225 related articles for article (PubMed ID: 34262257)
21. Comparison of methods to analyse susceptibility of German MDR/XDR Pseudomonas aeruginosa to ceftazidime/avibactam.
Schaumburg F; Bletz S; Mellmann A; Becker K; Idelevich EA
Int J Antimicrob Agents; 2019 Aug; 54(2):255-260. PubMed ID: 31071465
[TBL] [Abstract][Full Text] [Related]
22. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics.
Burgess DS; Frei CR
J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664
[TBL] [Abstract][Full Text] [Related]
23.
Karlowsky JA; Kazmierczak KM; Bouchillon SK; de Jonge BLM; Stone GG; Sahm DF
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760124
[TBL] [Abstract][Full Text] [Related]
24. Antibacterial Activity of Human Simulated Epithelial Lining Fluid Concentrations of Ceftazidime-Avibactam Alone or in Combination with Amikacin Inhale (BAY41-6551) against Carbapenem-Resistant Pseudomonas aeruginosa and Klebsiella pneumoniae.
Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29914950
[TBL] [Abstract][Full Text] [Related]
25. Supporting the ceftaroline fosamil/avibactam Enterobacteriaceae breakpoint determination using humanised in vivo exposures in a thigh model.
Bhalodi AA; Crandon JL; Williams G; Nicolau DP
Int J Antimicrob Agents; 2014 Dec; 44(6):508-13. PubMed ID: 25278330
[TBL] [Abstract][Full Text] [Related]
26. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004.
Wang H; Zhang B; Ni Y; Kuti JL; Chen B; Chen M; Nicolau DP
Int J Antimicrob Agents; 2007 Nov; 30(5):452-7. PubMed ID: 17646088
[TBL] [Abstract][Full Text] [Related]
27. Monte Carlo Simulation Methodologies for β-Lactam/β-Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments.
Kidd JM; Stein GE; Nicolau DP; Kuti JL
J Clin Pharmacol; 2020 Feb; 60(2):172-180. PubMed ID: 31423601
[TBL] [Abstract][Full Text] [Related]
28. In Vitro Activities of Ceftaroline/Avibactam, Ceftazidime/Avibactam, and Other Comparators Against Pathogens From Various Complicated Infections in China.
Zhou M; Cheng J; Liu Y; Hu Y; Liu Y; Lu J; Zhang S; Yu Y; Huang X; Yang Q; Liao K; Jin Y; Huang W; Feng X; Yang Q; Xu Y
Clin Infect Dis; 2018 Nov; 67(suppl_2):S206-S216. PubMed ID: 30423043
[TBL] [Abstract][Full Text] [Related]
29. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
[TBL] [Abstract][Full Text] [Related]
30. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
[TBL] [Abstract][Full Text] [Related]
31. Dynamic Emergence of Mismatch Repair Deficiency Facilitates Rapid Evolution of Ceftazidime-Avibactam Resistance in Pseudomonas aeruginosa Acute Infection.
Khil PP; Dulanto Chiang A; Ho J; Youn JH; Lemon JK; Gea-Banacloche J; Frank KM; Parta M; Bonomo RA; Dekker JP
mBio; 2019 Sep; 10(5):. PubMed ID: 31530672
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of ceftazidime-avibactam against Gram-negative isolates collected in 18 European countries, 2015-2017.
Stone GG; Seifert H; Nord CE
Int J Antimicrob Agents; 2020 Sep; 56(3):106045. PubMed ID: 32522673
[TBL] [Abstract][Full Text] [Related]
33. In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).
Piérard D; Stone GG
BMC Infect Dis; 2021 Jun; 21(1):600. PubMed ID: 34162341
[TBL] [Abstract][Full Text] [Related]
34. Steady-State Ceftazidime-Avibactam Serum Concentrations and Dosing Recommendations in a Critically Ill Patient Being Treated for Pseudomonas aeruginosa Pneumonia and Undergoing Continuous Venovenous Hemodiafiltration.
Soukup P; Faust AC; Edpuganti V; Putnam WC; McKinnell JA
Pharmacotherapy; 2019 Dec; 39(12):1216-1222. PubMed ID: 31596506
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the Efficacy of Optimized Two-Step-Administration Therapy with Ceftazidime/Avibactam for Treating Extensively Drug-Resistant Pseudomonas aeruginosa Pulmonary Infections: a Pharmacokinetic/Pharmacodynamic Analysis.
Kang Y; Cui J
Jpn J Infect Dis; 2023 Jan; 76(1):1-6. PubMed ID: 35908879
[TBL] [Abstract][Full Text] [Related]
36. Activity of ceftazidime-avibactam against fluoroquinolone-resistant Enterobacteriaceae and Pseudomonas aeruginosa.
Pitart C; Marco F; Keating TA; Nichols WW; Vila J
Antimicrob Agents Chemother; 2015; 59(6):3059-65. PubMed ID: 25753646
[TBL] [Abstract][Full Text] [Related]
37. Synergistic activities of ceftazidime-avibactam in combination with different antibiotics against colistin-nonsusceptible clinical strains of
Mataraci Kara E; Yilmaz M; İstanbullu Tosun A; Özbek Çelik B
Infect Dis (Lond); 2020 Sep; 52(9):616-624. PubMed ID: 32427010
[No Abstract] [Full Text] [Related]
38. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
[TBL] [Abstract][Full Text] [Related]
39. Validation of Sensititre Dry-Form Broth Microdilution Panels for Susceptibility Testing of Ceftazidime-Avibactam, a Broad-Spectrum-β-Lactamase Inhibitor Combination.
Jones RN; Holliday NM; Krause KM
Antimicrob Agents Chemother; 2015 Aug; 59(8):5036-9. PubMed ID: 26014937
[TBL] [Abstract][Full Text] [Related]
40.
Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
